title: The apolipoprotein B/A1 ratio is associated with reactive oxygen metabolites and endothelial dysfunction in statin-treated patients with coronary artery disease.
abstract: OBJECTIVE
  The prognostic significance of the apolipoprotein B/A1 (ApoB/A1) ratio in statintreated patients with coronary artery disease (CAD) is unknown. We aimed to evaluate the association of the ApoB/A1 ratio with oxidative stress and endothelial dysfunction in these patients.
  
  
  METHODS
  We enrolled 62 consecutive statin-treated patients who underwent percutaneous coronary intervention (PCI). Their lipid profiles, diacron-reactive oxygen metabolites (d-ROMs), as a marker of oxidative stress, flow-mediated dilatation (FMD), as a marker of vascular endothelial function, and C-reactive protein (CRP) levels, as a marker of inflammation, were measured.
  
  
  RESULTS
  Our study population comprised 44 men and 18 women (mean age, 70.5 ± 2.5 years). The ApoB/A1 ratio was positively correlated with the results of the d-ROMs test (p=0.004, r=0.36) and CRP level (p=0.02, r=0.30) and negatively correlated with the %FMD (p=0.005, r=-0.40). A multivariate logistic regression analysis showed that the most powerful predictive factor for the d-ROMs was the ApoB/A1 ratio (p=0.026). We therefore divided patients into two groups according to the cutoff point reported by the INTERHEART study: a low ApoB/A1 ratio (<0.641, n=26) and a high ApoB/A1 ratio (>0.641, n=36). The patients with a high ApoB/A1 ratio had higher levels of d-ROMs and CRP, and tended to have a lower %FMD.
  
  
  CONCLUSIONS
  The ApoB/A1 ratio was associated with the d-ROMs, a marker of oxidative stress, endothelial dysfunction and inflammation, and could be useful as a residual atherosclerotic risk marker to help prevent CAD in statin-treated patients.
authors.affiliation: Division of Cardiovascular Medicine, Department of Internal Medicine, Hyogo Prefectural Awaji Hospital, Hyogo, Japan.
authors.forename: Takuo
authors.initials: T
authors.lastname: Emoto
authors.forename: Takahiro
authors.initials: T
authors.lastname: Sawada
authors.forename: Natsumi
authors.initials: N
authors.lastname: Morimoto
authors.forename: Takako
authors.initials: T
authors.lastname: Tenjin
authors.forename: Taku
authors.initials: T
authors.lastname: Wakimoto
authors.forename: Fumie
authors.initials: F
authors.lastname: Ikeda
authors.forename: Chiaki
authors.initials: C
authors.lastname: Sato
authors.forename: Daisuke
authors.initials: D
authors.lastname: Terashita
authors.forename: Taiji
authors.initials: T
authors.lastname: Mizoguchi
authors.forename: Takao
authors.initials: T
authors.lastname: Mizuguchi
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Okamoto
authors.forename: Yosuke
authors.initials: Y
authors.lastname: Matsuo
authors.forename: Sushi-Ku
authors.initials: SK
authors.lastname: Kim
authors.forename: Akira
authors.initials: A
authors.lastname: Takarada
authors.forename: Mitsuhiro
authors.initials: M
authors.lastname: Yokoyama
mesh_terms: D000368:Aged; D016632:Apolipoprotein A-I / Q000097:blood*; D001055:Apolipoproteins B / Q000097:blood*; D003324:Coronary Artery Disease / Q000097:blood* / Q000188:drug therapy*; D004730:Endothelium, Vascular / Q000473:pathology*; D005260:Female; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D007249:Inflammation; D008297:Male; D008875:Middle Aged; D018384:Oxidative Stress; D010865:Pilot Projects; D011237:Predictive Value of Tests; D011379:Prognosis; D017382:Reactive Oxygen Species; D012307:Risk Factors
chemical_list: D016632:Apolipoprotein A-I; D001055:Apolipoproteins B; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D017382:Reactive Oxygen Species